White Paper On Drug Pricing Issues Within The Pharmaceutical Industry                      Available To BIO 2002 Attendees     What:          New white paper published for attendees of BIO 2002     When:          Monday, June 10, 2002 - Wednesday, June 12, 2002     Where:         Booth #2445 at BIO 2002     Who:           Joe Walsh, VP Decision Resources is available to discuss                   the white paper  

BIO 2002 Booth #2445 -- TORONTO, June 10 /PRNewswire/ -- Decision Resources announced today that it will distribute a brand new white paper to BIO 2002 attendees based on its recent report on pricing issues within the pharmaceutical industry. The report finds that pharmaceutical companies award themselves an average score of just 56% for the effectiveness of their pricing function. Devising the right pricing strategy for a new drug has never been more crucial or more complicated; however, many companies struggle to organize their pricing function for maximum effectiveness.

  (Photo:  http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    The report finds that:   -- Less than 50% of pharmaceutical companies have formalized or structured      the process for determining the first price estimate.   -- 70% of companies allocate funds for pricing research in an ad hoc      manner, with no fixed annual amounts.   -- 65% of companies have health economic units in their major affiliates,      but less than 20% have a dedicated employee or department with      responsibility for pricing matters at affiliate level.  

Decision Resources' How to Organize the Pharmaceutical Pricing Function is a strategic executive briefing from its Spectrum series. The white paper based on this report helps organizations determine:

  -- How should the pricing function be organized?  What role should a      central pricing department play?  How can health economics and      affiliates be integrated?   -- Why should pricing considerations feature prominently at every stage of      the product development process, from screening and candidate drug      selection to post-marketing life cycle management?  What steps are      necessary at each of seven critical stages?   -- What are the key elements in successful internal and external      communication of a pricing strategy?  What can be done to combat      parallel trade?  What factors should determine the launch sequence in      major markets?  

For further discussion of this issue or for those not available to attend BIO 2002, a conference call will be held on Tuesday, June 25, 2002 at 10:00 a.m. (EDT) to discuss the report findings. The call is available to all those who purchase the report; the white paper is free. Those interested in attending the teleconference should call Tim Daley at Decision Resources at 781-296-2636.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com  

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

Market for Deep Vein Thrombosis/Pulmonary Embolism is Poised for Significant Growth, According to a New Decision Resources' Study

View Now